Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wuxi Biologics Unsp/Adr (OP:WXXWY)

10.42 +0.11 (+1.07%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 44,881
Open 10.75
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.31
Today's Range 10.38 - 10.75
52wk Range 4.140 - 11.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs ↗
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
News headline image
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront ↗
Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. 
Via Talk Markets

Performance

YTD
+24.8%
+24.8%
1 Month
+8.9%
+8.9%
3 Month
+26.5%
+26.5%
6 Month
+35.6%
+35.6%
1 Year
+71.9%
+71.9%

More News

Read More
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Via Talk Markets
News headline image
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus ↗
Via Benzinga
News headline image
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement ↗
Via Talk Markets
News headline image
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗
Via Talk Markets
News headline image
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗
Via Talk Markets
News headline image
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal ↗
Via Talk Markets
News headline image
Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68 ↗
Via Benzinga
News headline image
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗
Via Talk Markets
News headline image
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio ↗
Via Talk Markets
Topics Initial Public Offering
News headline image
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact ↗
Via Talk Markets
News headline image
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion ↗
Via Talk Markets
News headline image
Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’ ↗
Via Talk Markets

Frequently Asked Questions

Is Wuxi Biologics Unsp/Adr publicly traded?
Yes, Wuxi Biologics Unsp/Adr is publicly traded.
What exchange does Wuxi Biologics Unsp/Adr trade on?
Wuxi Biologics Unsp/Adr trades on the OTC Traded
What is the ticker symbol for Wuxi Biologics Unsp/Adr?
The ticker symbol for Wuxi Biologics Unsp/Adr is WXXWY on the OTC Traded
What is the current price of Wuxi Biologics Unsp/Adr?
The current price of Wuxi Biologics Unsp/Adr is 10.42
When was Wuxi Biologics Unsp/Adr last traded?
The last trade of Wuxi Biologics Unsp/Adr was at 02/18/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.